Posts Tagged ‘enrollment’

AVEO Pharmaceuticals Initiates Patient Enrollment in Phase 1b Tivozanib Combination Trial in Advanced Solid Tumors

AVEO Pharmaceuticals Initiates Patient Enrollment in Phase 1b Tivozanib Combination Trial in Advanced Solid Tumors
AVEO Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine in patients with certain advanced solid tumors.

Read more on Business Wire via Yahoo! Finance

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has completed enrollment in the first of two dose cohorts in its Phase 1 clinical trial of PV-10 for liver cancer, and that the therapy was very well tolerated by all three subjects treated, with substantial evidence of efficacy.

Read more on News-Medical-Net

AVEO Achieves Enrollment Target Ahead of Schedule for Pivotal Phase 3 Trial of Tivozanib in Patients with Advanced …

AVEO Achieves Enrollment Target Ahead of Schedule for Pivotal Phase 3 Trial of Tivozanib in Patients with Advanced …
CAMBRIDGE, Mass.—-AVEO Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma .

Read more on Business Wire via Yahoo! Finance

Merrimack Pharmaceuticals And sanofi-aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 And …

Merrimack Pharmaceuticals And sanofi-aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 And …
Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today that the first patient has received an initial dose in a Phase 2 randomized double blind clinical study combining MM-121 with exemestane (Aromasin®) in breast cancer patients.

Read more on PharmaceuticalOnline

Biomoda Completes Patient Enrollment and Sample Collection in Pilot Study

Biomoda Completes Patient Enrollment and Sample Collection in Pilot Study
ALBUQUERQUE, N.M.—-Cancer diagnostics company Biomoda, Inc. today announced it completed patient enrollment and sample collection in a pilot study to determine the clinical sensitivity and specificity of its CyPath® labeling solution for the early detection of lung cancer.

Read more on Business Wire via Yahoo! Finance

OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC

OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).

Read more on News-Medical-Net

Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept

Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept
EpiCept Corporation today announced that the targeted enrollment in a Phase IIb trial for EpiCept NP-1 in chemotherapy-induced peripheral neuropathy has been attained. The trial is being conducted by National Cancer Institute -funded Community Clinical Oncology Program.

Read more on News-Medical-Net